financetom
Business
financetom
/
Business
/
Business First Bancshares Q3 net income rises 
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Business First Bancshares Q3 net income rises 
Oct 23, 2025 1:59 PM

Overview

* Business First Q3 net income rises to $21.5 mln, EPS at $0.73

* Company increases quarterly common dividend to $0.15 per share

* Successful conversion of Oakwood Bank systems completed

Outlook

* Company focuses on operational execution and M&A projects for future performance improvement

Result Drivers

* OAKWOOD CONVERSION - Successful conversion of Oakwood Bank systems onto Business First's platform completed in September 2025

* STABLE NET INTEREST INCOME - Net interest income increased to $69.3 mln, with net interest margin stable at 3.68%

* SECURITIES PORTFOLIO GROWTH - Securities portfolio increased by $59.5 mln, driven by purchases of mortgage-backed securities and fair value adjustments

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS $0.73

Q3 $21.20

Adjusted mln

Net

Income

Q3 Net $69.30

Interest mln

Income

Q3 Loan $1.63

Loss mln

Provisio

n

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the banks peer group is "buy"

* Wall Street's median 12-month price target for Business First Bancshares Inc ( BFST ) is $30.50, about 23.6% above its October 21 closing price of $23.31

* The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 9 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sector Update: Consumer Stocks Advance Premarket Thursday
Sector Update: Consumer Stocks Advance Premarket Thursday
Sep 11, 2025
09:14 AM EDT, 09/11/2025 (MT Newswires) -- Consumer stocks were advancing premarket Thursday, with the Consumer Discretionary Select Sector SPDR Fund ( XLY ) up 0.3% and the Consumer Staples Select Sector SPDR Fund ( XLP ) 0.1% higher. Alibaba Group ( BABA ) shares were up 3.1% after the company said it priced a $3.2 billion offering of zero...
XPEL Acquires Assets of Chinese Distributor
XPEL Acquires Assets of Chinese Distributor
Sep 11, 2025
09:09 AM EDT, 09/11/2025 (MT Newswires) -- XPEL ( XPEL ) said Thursday it has acquired the assets of its exclusive distributor in China aftermarket. Financial terms of the transaction were not disclosed. The transaction structure will result in XPEL ( XPEL ) owning a 76% interest in the Chinese entity conducting business in China. The company said the purchase...
T. Rowe Price Group August Assets Under Management Rise Month Over Month
T. Rowe Price Group August Assets Under Management Rise Month Over Month
Sep 11, 2025
09:13 AM EDT, 09/11/2025 (MT Newswires) -- T. Rowe Price ( TROW ) reported preliminary assets under management Thursday of $1.729 trillion as of Aug 31, up from $1.703 trillion in the previous month. The company said its equity assets rose to $867 billion at the end of August from $859 billion as of July 31, and multi-assets increased to...
Protagonist Says Johnson & Johnson Submits Application to EMA for Plaque Psoriasis Treatment
Protagonist Says Johnson & Johnson Submits Application to EMA for Plaque Psoriasis Treatment
Sep 11, 2025
09:12 AM EDT, 09/11/2025 (MT Newswires) -- Protagonist Therapeutics ( PTGX ) said Thursday that its partner, Johnson & Johnson ( JNJ ) , has submitted an application to the European Medicines Agency seeking approval of icotrokinra to treat moderate-to-severe plaque psoriasis in adults and adolescents above 12 years of age. The investigational oral tablet selectively blocks the IL-23 receptor,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved